The expanding pipeline
for juvenile idiopathic arthritis can be attributed to the increase in its
prevalence. One of the major factor that stimulate the growth of pipeline and
research is that the cause of juvenile idiopathic arthritis is not known. The juvenile
idiopathic arthritis occurs mostly in children before 16 years of age. Since
the disease occurs only in children, so the safety and efficacy concerns of the
drugs is given preference so that it can be treated without any side effects. Some
of the other factors driving the pipeline growth include, raising awareness of
health issues among children and less number of drugs available for therapy
against juvenile idiopathic arthritis. Currently, one in 1,000 child in the
U.S. suffers with juvenile idiopathic arthritis. Females are more susceptible
to juvenile idiopathic arthritis than males.
Explore Report at: https://www.psmarketresearch.com/market-analysis/juvenile-idiopathic-arthritis-therapeutics-pipeline-analysis
Juvenile
idiopathic arthritis can be symptomatized as swelling, joint pain, tenderness,
stiffness and fever that last for approximately more than 6 weeks. Juvenile
idiopathic arthritis, mostly occurs when body’s immune system erroneously
attacks its own healthy tissues and cells, which result in inflammation, pain,
heat, redness and swelling. Researchers have studied that, either environmental
factors or genetic tendency of child act as triggers for the occurrence of the
disease. Juvenile idiopathic arthritis affects mostly joints in knees, hand and
feet. Sometimes, severe complication can occur in children with juvenile
idiopathic arthritis such as eye inflammation. Currently, no medical test is
approved for diagnosis of juvenile idiopathic arthritis. Physicians diagnose juvenile
idiopathic arthritis by examining the medical history of the patient and the
result of other tests that help in ruling out other morbidities.
Some of the companies having a pipeline of juvenile idiopathic arthritis therapeutics include, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Pfizer, Inc., Novartis AG.
No comments:
Post a Comment